AZN.UK

11,274

-1.21%↓

HLN.UK

391.5

+2.25%↑

INDV

704

-3.76%↓

AZN.UK

11,274

-1.21%↓

HLN.UK

391.5

+2.25%↑

INDV

704

-3.76%↓

AZN.UK

11,274

-1.21%↓

HLN.UK

391.5

+2.25%↑

INDV

704

-3.76%↓

AZN.UK

11,274

-1.21%↓

HLN.UK

391.5

+2.25%↑

INDV

704

-3.76%↓

AZN.UK

11,274

-1.21%↓

HLN.UK

391.5

+2.25%↑

INDV

704

-3.76%↓

Search

GlaxoSmithKline PLC

Open

SectorHealthcare

1,470.5 -0.84

Overview

Share price change

24h

Current

Min

1466

Max

1483

Key metrics

By Trading Economics

Income

559M

501M

Sales

105M

8.1B

P/E

Sector Avg

23.952

73.239

EPS

0.232

Dividend yield

4.24

Profit margin

6.172

Employees

68,629

EBITDA

-52M

1.1B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+7.04% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.24%

3.06%

Next Earnings

30 Apr 2025

Next Dividend date

10 Apr 2025

Next Ex Dividend date

15 May 2025

Market Stats

By TradingEconomics

Market Cap

480M

61B

Previous open

1471.34

Previous close

1470.5

News Sentiment

By Acuity

71%

29%

353 / 386 Healthcare

GlaxoSmithKline PLC Chart

Past performance is not a reliable indicator of future results.

Related News

5 Feb 2025, 11:32 UTC

Earnings

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5 Feb 2025, 08:56 UTC

Earnings

Correction to GSK Article

5 Feb 2025, 08:24 UTC

Earnings

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5 Feb 2025, 07:43 UTC

Earnings

GSK Expects Further Profit Growth After Beating Market Views

13 Jan 2025, 07:14 UTC

Acquisitions, Mergers, Takeovers

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion

26 Mar 2025, 22:29 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 Mar 2025, 19:19 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 Mar 2025, 17:39 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19 Mar 2025, 14:50 UTC

Top News

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17 Mar 2025, 09:00 UTC

Top News

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24 Feb 2025, 07:05 UTC

Acquisitions, Mergers, Takeovers

GSK Completes Acquisition of IDRx

14 Feb 2025, 11:38 UTC

Top News
Earnings

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14 Feb 2025, 11:30 UTC

Top News
Earnings

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5 Feb 2025, 15:33 UTC

Market Talk
Earnings

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5 Feb 2025, 08:38 UTC

Market Talk
Earnings

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5 Feb 2025, 07:05 UTC

Earnings

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5 Feb 2025, 07:04 UTC

Earnings

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5 Feb 2025, 07:03 UTC

Earnings

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5 Feb 2025, 07:03 UTC

Earnings

GSK PLC Raises Mid-Term View

5 Feb 2025, 07:03 UTC

Earnings

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5 Feb 2025, 07:02 UTC

Earnings

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

5 Feb 2025, 07:02 UTC

Earnings

GSK PLC Issues GBP2B Buyback

5 Feb 2025, 07:01 UTC

Earnings

GSK PLC Declares 4Q Dividend of 16p

5 Feb 2025, 07:00 UTC

Earnings

GSK PLC 4Q Core EPS Consensus Was 20.6p

5 Feb 2025, 07:00 UTC

Earnings

GSK PLC 4Q Sales Consensus Was GBP7.83B

5 Feb 2025, 07:00 UTC

Earnings

GSK PLC 4Q Pretax Pft GBP563M

5 Feb 2025, 07:00 UTC

Earnings

GSK PLC 4Q EPS 10.0p

5 Feb 2025, 07:00 UTC

Earnings

GSK PLC 4Q Adj EPS 23.2p

5 Feb 2025, 07:00 UTC

Earnings

GSK PLC 4Q Oper Pft GBP696M

13 Jan 2025, 07:05 UTC

Acquisitions, Mergers, Takeovers

GSK Enters Agreement To Acquire IDRx, Inc. >GSK.LN

Peer Comparison

Price change

GlaxoSmithKline PLC Forecast

Price Target

By TipRanks

7.04% upside

12 Months Forecast

Average 1,593.33 GBX  7.04%

High 2,290 GBX

Low 1,450 GBX

Based on 12 Wall Street analysts offering 12 month price targets forGlaxoSmithKline PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

12 ratings

2

Buy

8

Hold

2

Sell

Sentiment

By Acuity

353 / 386 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.